NEW DELHI, Dec 16: Drug major Cipla on Wednesday announced its partnership with the Premier Medical Corporation Pvt Ltd for commercialisation of the rapid antigen test kits for COVID-19 in India.
“In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd,” Cipla said in a regulatory filing.
The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week.
The test will be marketed under the brand name ‘CIPtest’.
(PTI)
Follow our WhatsApp channel
